Wall Street Analysts See a 33.27% Upside in Edgewise Therapeutics, Inc. (EWTX): Can the Stock Really Move This High?
https://www.zacks.com/stock/news/2224151/wall-street-analysts-see-a-33-27-upside-in-edgewise-therapeutics-inc-ewtx-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2224151
Feb 09, 2024 - The mean of analysts' price targets for Edgewise Therapeutics, Inc. (EWTX) points to a 33.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
0
Wall Street Analysts See a 39.25% Upside in Altus Power, Inc. (AMPS): Can the Stock Really Move This High?
https://www.zacks.com/stock/news/2224816/wall-street-analysts-see-a-39-25-upside-in-altus-power-inc-amps-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2224816
Feb 12, 2024 - The average of price targets set by Wall Street analysts indicates a potential upside of 39.3% in Altus Power, Inc. (AMPS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
0
Wall Street Analysts See Builders FirstSource (BLDR) as a Buy: Should You Invest?
https://www.zacks.com/stock/news/2227905/wall-street-analysts-see-builders-firstsource-bldr-as-a-buy-should-you-invest?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2227905
Feb 19, 2024 - The average brokerage recommendation (ABR) for Builders FirstSource (BLDR) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
0
Sealed Air (SEE) to Report Q4 Earnings: What to Expect?
https://www.zacks.com/stock/news/2230384/sealed-air-see-to-report-q4-earnings-what-to-expect?cid=CS-ZC-FT-analyst_blog|earnings_preview-2230384
Feb 22, 2024 - Sealed Air's (SEE) Q4 results are likely to bear lower volumes, owing to recessionary pressures in the industrial and fulfillment market, and food market declines.
0
Wall Street Analysts See a 56.18% Upside in Morphic Holding, Inc. (MORF): Can the Stock Really Move This High?
https://www.zacks.com/stock/news/2231768/wall-street-analysts-see-a-56-18-upside-in-morphic-holding-inc-morf-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2231768
Feb 26, 2024 - The average of price targets set by Wall Street analysts indicates a potential upside of 56.2% in Morphic Holding, Inc. (MORF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
0
Wall Street Analysts See a 131.6% Upside in Relay Therapeutics, Inc. (RLAY): Can the Stock Really Move This High?
https://www.zacks.com/stock/news/2231767/wall-street-analysts-see-a-131-6-upside-in-relay-therapeutics-inc-rlay-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2231767
Feb 26, 2024 - The mean of analysts' price targets for Relay Therapeutics, Inc. (RLAY) points to a 131.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
0
Sealed Air (SEE) Q4 Earnings & Revenues Surpass Estimates
https://www.zacks.com/stock/news/2232562/sealed-air-see-q4-earnings-revenues-surpass-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2232562
Feb 27, 2024 - Sealed Air (SEE) witnesses year-over-year declines in its Q4 top and bottom lines due to lower volumes.
0
Wall Street Analysts See a 58.85% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High?
https://www.zacks.com/stock/news/2234650/wall-street-analysts-see-a-58-85-upside-in-arcutis-biotherapeutics-inc-arqt-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2234650
Mar 01, 2024 - The consensus price target hints at a 58.9% upside potential for Arcutis Biotherapeutics, Inc. (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
0
Wall Street Analysts See ANI (ANIP) as a Buy: Should You Invest?
https://www.zacks.com/stock/news/2234557/wall-street-analysts-see-ani-anip-as-a-buy-should-you-invest?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2234557
Mar 01, 2024 - Based on the average brokerage recommendation (ABR), ANI (ANIP) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
0
Dave & Buster's (PLAY) Sees a More Significant Dip Than Broader Market: Some Facts to Know
https://www.zacks.com/stock/news/2235661/dave-buster-s-play-sees-a-more-significant-dip-than-broader-market-some-facts-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2235661
Mar 04, 2024 - In the latest trading session, Dave & Buster's (PLAY) closed at $61.30, marking a -1.89% move from the previous day.
0